Eyepoint Pharmaceuticals logo

Eyepoint Pharmaceuticals Share Price Today

(NASDAQ: EYPT)

Eyepoint Pharmaceuticals share price is $6.58 & ₹572.26 as on 6 Mar 2025, 2.30 'hrs' IST

$6.58

0.5

(8.22%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Eyepoint Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Eyepoint Pharmaceuticals stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Eyepoint Pharmaceuticals, along with analyst recommendations, forecasts, and comprehensive financials.

Eyepoint Pharmaceuticals share price movements

  • Today's Low: $5.97
    Today's High: $6.60

    Day's Volatility :9.62%

  • 52 Weeks Low: $5.54
    52 Weeks High: $26.76

    52 Weeks Volatility :79.3%

Eyepoint Pharmaceuticals (EYPT) Returns

PeriodEyepoint Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
-19.36%
3.7%
0.0%
6 Months
-18.36%
-2.8%
0.0%
1 Year
-74.44%
2.5%
0.0%
3 Years
-45.26%
12.9%
-11.6%

Eyepoint Pharmaceuticals (EYPT) Key Statistics

in dollars & INR

Previous Close
$6.08
Open
$6.33
Today's High
$6.6
Today's Low
$5.965
Market Capitalization
$415.0M
Today's Volume
$955.0K
52 Week High
$26.7629
52 Week Low
$5.54
Revenue TTM
$45.7M
EBITDA
$-114.6M
Earnings Per Share (EPS)
$-2.11
Profit Margin
-226.57%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-74.68%

How to invest in Eyepoint Pharmaceuticals Stock (EYPT) from India?

It is very easy for Indian residents to invest directly in Eyepoint Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Eyepoint Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Eyepoint Pharmaceuticals or EYPT on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Eyepoint Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Eyepoint Pharmaceuticals shares which would translate to 0.132 fractional shares of Eyepoint Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Eyepoint Pharmaceuticals, in just a few clicks!

Returns in Eyepoint Pharmaceuticals (EYPT) for Indian investors in Rupees

The Eyepoint Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Eyepoint Pharmaceuticals investment value today

Current value as on today

₹30,512

Returns

₹69,488

(-69.49%)

Returns from Eyepoint Pharmaceuticals Stock

₹74,437 (-74.44%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Eyepoint Pharmaceuticals (EYPT)

43%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Eyepoint Pharmaceuticals Stock from India on INDmoney has increased by 43% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Eyepoint Pharmaceuticals

  • Cormorant Asset Management, LLC

    12.20%

  • Suvretta Capital Management, LLC

    9.94%

  • Adage Capital Partners Gp LLC

    8.42%

  • BlackRock Inc

    7.74%

  • Franklin Resources Inc

    6.06%

  • Vanguard Group Inc

    5.57%

Analyst Recommendation on Eyepoint Pharmaceuticals

Buy

    93%Buy

    6%Hold

    0%Sell

Based on 16 Wall street analysts offering stock ratings for Eyepoint Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
15
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Eyepoint Pharmaceuticals Stock (EYPT)

What analysts predicted

Upside of 407.85%

Target:

$33.42

Current:

$6.58

Insights on Eyepoint Pharmaceuticals Stock (Ticker Symbol: EYPT)

  • Price Movement

    In the last 7 days, EYPT stock has moved up by 5.6%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 9.47M → 10.52M (in $), with an average increase of 10.0% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -30.82M → -29.36M (in $), with an average increase of 5.0% per quarter
  • EYPT vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.5% return, outperforming this stock by 140.9%
  • EYPT vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 51.6% return, outperforming this stock by 94.1%
  • Price to Sales

    ForEYPT every $1 of sales, investors are willing to pay $7.3, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

EYPT Eyepoint Pharmaceuticals Financials in INR & Dollars

FY18Y/Y Change
Revenue
$3.0M
↓ 60.72%
Net Income
$-53.2M
↑ 187.64%
Net Profit Margin
-1.8K%
↓ 1550.52%
FY19Y/Y Change
Revenue
$20.4M
↑ 587.77%
Net Income
$-63.0M
↑ 18.43%
Net Profit Margin
-309.2%
↑ 1486.51%
FY20Y/Y Change
Revenue
$34.4M
↑ 69.1%
Net Income
$-52.7M
↓ 16.39%
Net Profit Margin
-152.89%
↑ 156.31%
FY21Y/Y Change
Revenue
$36.9M
↑ 7.27%
Net Income
$-63.9M
↑ 21.39%
Net Profit Margin
-173.03%
↓ 20.14%
FY22Y/Y Change
Revenue
$41.4M
↑ 12.09%
Net Income
$-124.5M
↑ 94.81%
Net Profit Margin
-300.72%
↓ 127.69%
FY23Y/Y Change
Revenue
$46.0M
↑ 11.14%
Net Income
$-70.8M
↓ 43.14%
Net Profit Margin
-153.84%
↑ 146.88%
Q2 FY23Q/Q Change
Revenue
$9.1M
↑ 18.51%
Net Income
$-22.9M
↑ 6.18%
Net Profit Margin
-251.73%
↑ 29.23%
Q3 FY23Q/Q Change
Revenue
$15.2M
↑ 66.96%
Net Income
$-12.6M
↓ 44.97%
Net Profit Margin
-82.96%
↑ 168.77%
Q4 FY23Q/Q Change
Revenue
$14.0M
↓ 7.72%
Net Income
$-14.1M
↑ 11.79%
Net Profit Margin
-100.51%
↓ 17.55%
Q1 FY24Q/Q Change
Revenue
$11.7M
↓ 16.71%
Net Income
$-29.3M
↑ 107.7%
Net Profit Margin
-250.63%
↓ 150.12%
Q2 FY24Q/Q Change
Revenue
$9.5M
↓ 18.89%
Net Income
$-30.8M
↑ 5.27%
Net Profit Margin
-325.27%
↓ 74.64%
Q3 FY24Q/Q Change
Revenue
$10.5M
↑ 11.05%
Net Income
$-29.4M
↓ 4.75%
Net Profit Margin
-278.99%
↑ 46.28%
FY18Y/Y Change
Profit
$-15.5M
↓ 306.14%
FY19Y/Y Change
Profit
$17.7M
↓ 213.75%
FY20Y/Y Change
Profit
$28.6M
↑ 61.86%
FY21Y/Y Change
Profit
$28.8M
↑ 0.52%
FY22Y/Y Change
Profit
$33.1M
↑ 15.01%
FY23Y/Y Change
Profit
$41.4M
↑ 25.12%
Q2 FY23Q/Q Change
Profit
$7.3M
↑ 3.83%
Q3 FY23Q/Q Change
Profit
$14.0M
↑ 91.44%
Q4 FY23Q/Q Change
Profit
$13.0M
↓ 6.93%
Q1 FY24Q/Q Change
Profit
$10.9M
↓ 16.16%
Q2 FY24Q/Q Change
Profit
$8.1M
↓ 26.08%
Q3 FY24Q/Q Change
Profit
$9.8M
↑ 21.2%
FY18Y/Y Change
Operating Cash Flow
$-21.9M
↑ 6.92%
Investing Cash Flow
$-17.0M
↑ 0.4%
Financing Cash Flow
$60.7M
↑ 613.52%
FY19Y/Y Change
Operating Cash Flow
$-56.7M
↑ 158.82%
Investing Cash Flow
$-213.0K
↓ 98.74%
Financing Cash Flow
$33.9M
↓ 44.18%
FY20Y/Y Change
Operating Cash Flow
$-14.4M
↓ 74.54%
Investing Cash Flow
$-362.0K
↑ 69.95%
Financing Cash Flow
$37.5M
↑ 10.71%
FY21Y/Y Change
Operating Cash Flow
$-50.1M
↑ 247.05%
Investing Cash Flow
$-33.1M
↑ 9049.45%
Financing Cash Flow
$216.9M
↑ 478.53%
FY22Y/Y Change
Operating Cash Flow
$-65.0M
↑ 29.76%
Investing Cash Flow
$-17.3M
↓ 47.87%
Financing Cash Flow
$-690.0K
↓ 100.32%
Q2 FY23Q/Q Change
Operating Cash Flow
$57.0M
↓ 438.72%
Investing Cash Flow
$13.5M
↓ 58.03%
Financing Cash Flow
$-36.7M
↑ 616.12%

Eyepoint Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Eyepoint Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Eyepoint Pharmaceuticals (EYPT) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Eyepoint Pharmaceuticals Inc logo
-13.65%
-18.36%
-74.44%
-45.26%
-38.5%
Regeneron Pharmaceuticals, Inc. logo
-3.09%
-40.28%
-29.31%
11.08%
44.83%
Beone Medicines Ltd logo
15.43%
36.87%
64.37%
45.89%
71.3%
Vertex Pharmaceuticals Incorporated logo
0.82%
4.92%
19.37%
108.73%
123.83%
Alnylam Pharmaceuticals, Inc. logo
-10.36%
-0.89%
66.53%
52.9%
126.66%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Eyepoint Pharmaceuticals Inc logo
NA
NA
NA
-2.17
-0.75
-0.31
NA
4.09
Regeneron Pharmaceuticals, Inc. logo
17.86
17.86
1.01
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.34
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Eyepoint Pharmaceuticals Inc logo
Buy
$415.0M
-38.5%
NA
-226.57%
Regeneron Pharmaceuticals, Inc. logo
Buy
$73.8B
44.83%
17.86
31.07%
Beone Medicines Ltd logo
NA
$29.1B
71.3%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.9B
123.83%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.4B
126.66%
NA
-12.37%

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Organization
Eyepoint Pharmaceuticals
Employees
121
CEO
Dr. Jay S. Duker M.D.
Industry
Health Technology

Management People of Eyepoint Pharmaceuticals

NameTitle
Dr. Jay S. Duker M.D.
President, CEO & Director
Mr. George O. Elston CPA
Executive VP & CFO
Mr. Ron I. Honig Esq.
Chief Legal Officer & Company Secretary
Ms. Jennifer Leonard
Chief People Officer & Senior VP of IT
Mr. David Scott Jones M.A.
Senior VP & Chief Commercial Officer
Mr. Michael Pine
Chief Business Officer
Ms. Isabelle Lefebvre
Chief Regulatory Officer
Mr. Michael J. Maciocio
Chief Manufacturing Officer
Dr. Marcia Sellos-Moura Ph.D.
Senior VP and Head of Development & Program Management
Dr. Ramiro Ribeiro M.D., Ph.D.
Chief Medical Officer

Important FAQs about investing in EYPT Stock from India :

What is Eyepoint Pharmaceuticals share price today?

Eyepoint Pharmaceuticals share price today stands at $6.58, Open: $6.33 ; Previous Close: $6.08 ; High: $6.60 ; Low: $5.97 ; 52 Week High: $26.76 ; 52 Week Low: $5.54.

The stock opens at $6.33, after a previous close of $6.08. The stock reached a daily high of $6.60 and a low of $5.97, with a 52-week high of $26.76 and a 52-week low of $5.54.

Can Indians buy Eyepoint Pharmaceuticals shares?

Yes, Indians can invest in the Eyepoint Pharmaceuticals (EYPT) from India.

With INDmoney, you can buy Eyepoint Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Eyepoint Pharmaceuticals at zero transaction cost.

How can I buy Eyepoint Pharmaceuticals shares from India?

It is very easy to buy Eyepoint Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Eyepoint Pharmaceuticals (EYPT) be purchased?

Yes, you can buy fractional shares of Eyepoint Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Eyepoint Pharmaceuticals stocks?

To start investing in Eyepoint Pharmaceuticals, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Eyepoint Pharmaceuticals Stock (EYPT)?

Today’s highest price of Eyepoint Pharmaceuticals (EYPT) is $6.60.

Today’s lowest price of Eyepoint Pharmaceuticals (EYPT) is $5.97.

What is today's market capitalisation of Eyepoint Pharmaceuticals?

Today's market capitalisation of Eyepoint Pharmaceuticals EYPT is 415.0M

What is the 52 Week High and Low Range of Eyepoint Pharmaceuticals Stock (EYPT)?

  • 52 Week High

    $26.76

  • 52 Week Low

    $5.54

What are the historical returns of Eyepoint Pharmaceuticals (EYPT)?

  • 1 Month Returns

    -13.65%

  • 3 Months Returns

    -18.36%

  • 1 Year Returns

    -74.44%

  • 5 Years Returns

    -38.5%

Who is the Chief Executive Officer (CEO) of Eyepoint Pharmaceuticals ?

Dr. Jay S. Duker M.D. is the current Chief Executive Officer (CEO) of Eyepoint Pharmaceuticals.